Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ISIS-3521. Isis Pharmaceuticals.

K Li1, J Zhang

  • 1King/Drew Medical Center, Los Angeles, CA 90059, USA. kali@cdrewu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|March 14, 2002
PubMed
Summary

ISIS-3521, an investigational drug, is being developed as a treatment for solid tumors. Phase III trials are underway for non-small cell lung cancer (NSCLC).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Superantigen reactivity of gamma delta T cell clones isolated from patients with multiple sclerosis and controls.

Cellular immunology·1995
Same author

Tissue distribution of cocaine methyl esterase and ethyl transferase activities: correlation with carboxylesterase protein.

The Journal of pharmacology and experimental therapeutics·1995
Same author

Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E.

The American journal of pathology·1995
Same author

Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter.

Molecular and cellular biology·1995
Same author

A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity.

Nature genetics·1995

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • ISIS-3521 is an antisense oligonucleotide inhibitor of protein kinase C alpha (PKCa) expression.
  • It is being developed for solid tumors refractory to standard treatments.

Purpose of the Study:

  • To evaluate ISIS-3521 for the treatment of solid tumors, particularly non-small cell lung cancer (NSCLC).

Main Methods:

  • Phase III clinical trials initiated in October 2000 for ISIS-3521 in combination with carboplatin and paclitaxel for NSCLC.
  • FDA granted Fast Track review status for NSCLC in November 2000.

Main Results:

  • Eli Lilly in-licensed ISIS-3521 in August 2001.
  • A strategic alliance between Eli Lilly and Isis includes ISIS-3521, with Isis receiving $25 million upfront and reimbursement for phase III costs.

Conclusions:

  • ISIS-3521 shows potential for treating solid tumors, especially NSCLC.
  • Regulatory and commercial developments indicate ongoing progress in its development.

Related Experiment Videos